Precision BioSciences, Inc. (NASDAQ:DTIL) Stock Has Average Target Price of $32.25

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have earned a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $32.25.

Several equities analysts have recently issued reports on DTIL shares. HC Wainwright reiterated a “buy” rating on shares of Precision BioSciences in a research note on Monday, August 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Precision BioSciences in a research note on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of Precision BioSciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th.

Precision BioSciences Price Performance

Shares of NASDAQ DTIL opened at $6.03 on Monday. The business’s fifty day simple moving average is $7.15 and its 200-day simple moving average is $7.19. Precision BioSciences has a 12-month low of $3.53 and a 12-month high of $9.62. The company has a current ratio of 12.82, a quick ratio of 12.82 and a debt-to-equity ratio of 0.50.

Precision BioSciences (NASDAQ:DTIL) last released its earnings results on Thursday, August 6th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative return on equity of 72.52% and a negative net margin of 96.73%. As a group, equities research analysts expect that Precision BioSciences will post -3.33 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Engineers Gate Manager LP acquired a new stake in shares of Precision BioSciences in the 2nd quarter valued at $164,000. Squarepoint Ops LLC lifted its position in shares of Precision BioSciences by 212.7% during the 2nd quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock worth $1,078,000 after purchasing an additional 93,258 shares during the last quarter. Corient Private Wealth LP lifted its position in shares of Precision BioSciences by 70.4% during the 2nd quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock worth $1,926,000 after purchasing an additional 101,206 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Precision BioSciences during the 2nd quarter worth $467,000. Finally, Bank of America Corp DE grew its stake in shares of Precision BioSciences by 167.6% during the first quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock worth $151,000 after purchasing an additional 17,172 shares in the last quarter. Institutional investors and hedge funds own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc is a biotechnology company developing gene-editing therapies for serious diseases. The company’s work is based primarily on its proprietary ARCUS platform, which uses engineered nucleases designed to make precise changes to DNA inside the body.

Precision BioSciences is focused on in vivo gene editing programs addressing conditions including chronic hepatitis B, Duchenne muscular dystrophy and alpha-1 antitrypsin deficiency. Its development efforts are intended to remove, insert or repair genetic material and potentially provide durable treatments after a single administration.

Founded in 2006 and headquartered in Durham, North Carolina, the company has also pursued cell therapy programs and strategic collaborations to apply its gene-editing technology to additional therapeutic areas.